Cargando…

Prevalence of long COVID in a national cohort: longitudinal measures from disease onset until 8 months’ follow-up

OBJECTIVES: Persistence of COVID-19 symptoms in nonhospitalized individuals beyond a few months has not been well characterized. In this longitudinal study from the Faroe Islands, we present prevalence of long COVID in mainly nonhospitalized patients who were followed up for up to 8 months. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Petersen, Maria Skaalum, Kristiansen, Marnar Fríðheim, Hanusson, Katrin Dahl, Foldbo, Billa Mouritsardóttir, Danielsen, Marjun Eivindardóttir, á Steig, Bjarni, Gaini, Shahin, Strøm, Marin, Weihe, Pál
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222150/
https://www.ncbi.nlm.nih.gov/pubmed/35753603
http://dx.doi.org/10.1016/j.ijid.2022.06.031
_version_ 1784732802070085632
author Petersen, Maria Skaalum
Kristiansen, Marnar Fríðheim
Hanusson, Katrin Dahl
Foldbo, Billa Mouritsardóttir
Danielsen, Marjun Eivindardóttir
á Steig, Bjarni
Gaini, Shahin
Strøm, Marin
Weihe, Pál
author_facet Petersen, Maria Skaalum
Kristiansen, Marnar Fríðheim
Hanusson, Katrin Dahl
Foldbo, Billa Mouritsardóttir
Danielsen, Marjun Eivindardóttir
á Steig, Bjarni
Gaini, Shahin
Strøm, Marin
Weihe, Pál
author_sort Petersen, Maria Skaalum
collection PubMed
description OBJECTIVES: Persistence of COVID-19 symptoms in nonhospitalized individuals beyond a few months has not been well characterized. In this longitudinal study from the Faroe Islands, we present prevalence of long COVID in mainly nonhospitalized patients who were followed up for up to 8 months. METHODS: All Faroese individuals with confirmed COVID-19 diagnosis from August to December 2020 were invited to participate in this study (n = 297). Demographic and clinical characteristics and self-reported symptoms were ascertained prospectively using a detailed questionnaire administered at repeated phone interviews. RESULTS: A total of 226 individuals participated at baseline (226/297, 76% participation rate), of whom 170 participants had more than 3 months follow-up. Of these, 39% (n = 67/170, 95% confidence interval [CI] 32-37%) reported persistent symptoms (median [range] 168 [93-231] days) after the acute phase and 8% (n = 14/170, 95% CI 5-13%) reported severe persistent symptoms. The most prevalent symptoms were fatigue (17%) and smell (17%) and taste (14%) dysfunction. Long COVID was more common in people reporting daily medication use (odds ratio 2.34, 95% CI 1.02-5.37). CONCLUSION: Our results show that symptoms may take months to resolve, even among nonhospitalized individuals, with a mild illness in the acute phase. Continued monitoring for long COVID is needed to evaluate the added risk of a potential public health concern.
format Online
Article
Text
id pubmed-9222150
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-92221502022-06-24 Prevalence of long COVID in a national cohort: longitudinal measures from disease onset until 8 months’ follow-up Petersen, Maria Skaalum Kristiansen, Marnar Fríðheim Hanusson, Katrin Dahl Foldbo, Billa Mouritsardóttir Danielsen, Marjun Eivindardóttir á Steig, Bjarni Gaini, Shahin Strøm, Marin Weihe, Pál Int J Infect Dis Article OBJECTIVES: Persistence of COVID-19 symptoms in nonhospitalized individuals beyond a few months has not been well characterized. In this longitudinal study from the Faroe Islands, we present prevalence of long COVID in mainly nonhospitalized patients who were followed up for up to 8 months. METHODS: All Faroese individuals with confirmed COVID-19 diagnosis from August to December 2020 were invited to participate in this study (n = 297). Demographic and clinical characteristics and self-reported symptoms were ascertained prospectively using a detailed questionnaire administered at repeated phone interviews. RESULTS: A total of 226 individuals participated at baseline (226/297, 76% participation rate), of whom 170 participants had more than 3 months follow-up. Of these, 39% (n = 67/170, 95% confidence interval [CI] 32-37%) reported persistent symptoms (median [range] 168 [93-231] days) after the acute phase and 8% (n = 14/170, 95% CI 5-13%) reported severe persistent symptoms. The most prevalent symptoms were fatigue (17%) and smell (17%) and taste (14%) dysfunction. Long COVID was more common in people reporting daily medication use (odds ratio 2.34, 95% CI 1.02-5.37). CONCLUSION: Our results show that symptoms may take months to resolve, even among nonhospitalized individuals, with a mild illness in the acute phase. Continued monitoring for long COVID is needed to evaluate the added risk of a potential public health concern. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022-09 2022-06-23 /pmc/articles/PMC9222150/ /pubmed/35753603 http://dx.doi.org/10.1016/j.ijid.2022.06.031 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Petersen, Maria Skaalum
Kristiansen, Marnar Fríðheim
Hanusson, Katrin Dahl
Foldbo, Billa Mouritsardóttir
Danielsen, Marjun Eivindardóttir
á Steig, Bjarni
Gaini, Shahin
Strøm, Marin
Weihe, Pál
Prevalence of long COVID in a national cohort: longitudinal measures from disease onset until 8 months’ follow-up
title Prevalence of long COVID in a national cohort: longitudinal measures from disease onset until 8 months’ follow-up
title_full Prevalence of long COVID in a national cohort: longitudinal measures from disease onset until 8 months’ follow-up
title_fullStr Prevalence of long COVID in a national cohort: longitudinal measures from disease onset until 8 months’ follow-up
title_full_unstemmed Prevalence of long COVID in a national cohort: longitudinal measures from disease onset until 8 months’ follow-up
title_short Prevalence of long COVID in a national cohort: longitudinal measures from disease onset until 8 months’ follow-up
title_sort prevalence of long covid in a national cohort: longitudinal measures from disease onset until 8 months’ follow-up
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9222150/
https://www.ncbi.nlm.nih.gov/pubmed/35753603
http://dx.doi.org/10.1016/j.ijid.2022.06.031
work_keys_str_mv AT petersenmariaskaalum prevalenceoflongcovidinanationalcohortlongitudinalmeasuresfromdiseaseonsetuntil8monthsfollowup
AT kristiansenmarnarfriðheim prevalenceoflongcovidinanationalcohortlongitudinalmeasuresfromdiseaseonsetuntil8monthsfollowup
AT hanussonkatrindahl prevalenceoflongcovidinanationalcohortlongitudinalmeasuresfromdiseaseonsetuntil8monthsfollowup
AT foldbobillamouritsardottir prevalenceoflongcovidinanationalcohortlongitudinalmeasuresfromdiseaseonsetuntil8monthsfollowup
AT danielsenmarjuneivindardottir prevalenceoflongcovidinanationalcohortlongitudinalmeasuresfromdiseaseonsetuntil8monthsfollowup
AT asteigbjarni prevalenceoflongcovidinanationalcohortlongitudinalmeasuresfromdiseaseonsetuntil8monthsfollowup
AT gainishahin prevalenceoflongcovidinanationalcohortlongitudinalmeasuresfromdiseaseonsetuntil8monthsfollowup
AT strømmarin prevalenceoflongcovidinanationalcohortlongitudinalmeasuresfromdiseaseonsetuntil8monthsfollowup
AT weihepal prevalenceoflongcovidinanationalcohortlongitudinalmeasuresfromdiseaseonsetuntil8monthsfollowup